UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)

Lixte Biotechnology Holdings, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

539319 10 3

(CUSIP Number)

January 21, 2016

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[  ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[  ] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall not be subject to all other provisions of the Act (however, see the Notes).

¹Consists of 4,850,000 shares of common stock and 4,375,000 shares of common stock issuable upon conversion of the Company’s Series A Convertible Preferred Stock held by the Arthur and Jane Riggs 1990 Revocable Trust, of which Dr. Riggs and his wife, Jane Riggs, are co-trustees. Dr. and Mrs. Riggs, as co-trustees of the trust, share voting and dispositive power over the shares.

²Based on 47,875,814 shares outstanding as of October 31, 2015, as reflected in the Issuer’s Form 10-Q for the quarter ended September 30, 2015.

⁽¹⁾ Consists of 4,850,000 shares of common stock and 4,375,000 shares of common stock issuable upon conversion of the Company’s Series A Convertible Preferred Stock held by the Arthur and Jane Riggs 1990 Revocable Trust, of which Dr. Riggs and his wife, Jane Riggs, are co-trustees. Dr. and Mrs. Riggs, as co-trustees of the trust, share voting and dispositive power over the shares.

⁽²⁾ Based on 47,875,814 shares outstanding as of October 31, 2015, as reflected in the Issuer’s Form 10-Q for the quarter ended September 30, 2015.

Item 1(a). Name of Issuer.

The name of the issuer is Lixte Biotechnology Holdings, Inc. (the “Issuer”).

Item 1(b). Address of Issuer’s Principal Executive Offices.

The address of the Issuer’s principal executive office is 248 Route 25A, No. 2, East Setauket, New York 11733.

Item 2(a). Name of Person Filing.

The names of the individuals are Arthur Riggs and Jane Riggs (each a “Reporting Person” and, collectively, the “Reporting Persons”). The Reporting Persons are husband and wife and hold the shares reported in Rows 5 & 7 of their respective cover pages co-trustees of a trust.

Item 2(b). Address of Principal Business Office, or, if None, Residence.

The address of Arthur Riggs is 4852 Saint Andres Ave., La Verne, CA 91750

The address of Jane Riggs is 4852 Saint Andres Ave., La Verne, CA 91750 .

Item 2(c). Citizenship.

Arthur Riggs is a United States citizen.

Jane Riggs is a United States citizen.

Item 2(d). Title of Class of Securities.

The title of the class of securities to which this statement relates is the common stock of the Issuer, $0.0001 par value per share (the “Common Stock”).

Item 2(e). CUSIP No.

The CUSIP number is 539319103.

The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover pages and is incorporated herein by reference.

If this Schedule is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

Not Applicable.

Not Applicable.

Not Applicable.

Not Applicable.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.